AAV-based vectors for human diseases modeling in laboratory animals
The development of therapeutic drugs and vaccines requires the availability of appropriate model animals that replicate the pathogenesis of human diseases. Both native and transgenic animals can be utilized as models. The advantage of transgenic animals lies in their ability to simulate specific pro...
Saved in:
Main Authors: | Timur I. Aliev, Dmitry V. Yudkin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1499605/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recombinant AAV batch profiling by nanopore sequencing elucidates product-related DNA impurities and vector genome length distribution
by: Florian Dunker-Seidler, et al.
Published: (2025-03-01) -
Systemic delivery of AAV5, AAV8, and AAV9 packaging a C5-12-microdystrophin-FLAG expression cassette in non-human primates
by: Mengping Liu, et al.
Published: (2025-03-01) -
Probing aspects of extracellular vesicle associated AAV allows increased vector yield and insight into its transduction and immune-evasive properties
by: Ming Cheng, et al.
Published: (2025-03-01) -
Development of cell lines with increased susceptibility to diverse adeno-associated viral vectors to enable in vitro potency assays
by: James Zengel, et al.
Published: (2025-03-01) -
Advances in Gene Therapy for Neurologic Disorders: An Overview
by: Pallavi Chand, et al.
Published: (2025-02-01)